Literature DB >> 15471565

Activation of human IK and SK Ca2+ -activated K+ channels by NS309 (6,7-dichloro-1H-indole-2,3-dione 3-oxime).

Dorte Strøbaek1, Lene Teuber, Tino D Jørgensen, Philip K Ahring, Katrine Kjaer, Rie S Hansen, Søren Peter Olesen, Palle Christophersen, Bo Skaaning-Jensen.   

Abstract

We have identified and characterized the compound NS309 (6,7-dichloro-1H-indole-2,3-dione 3-oxime) as a potent activator of human Ca2+ -activated K+ channels of SK and IK types, whereas it is devoid of effect on BK type channels. IK- and SK-channels have previously been reported to be activated by the benzimidazolinone, 1-EBIO and more potently by its dichloronated-analogue, DC-EBIO. NS309 is at least 1000 times more potent than 1-EBIO and at least 30 times more potent than DC-EBIO when the compounds are compared on the same cell.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15471565     DOI: 10.1016/j.bbamem.2004.07.006

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  94 in total

1.  Endogenous and Agonist-induced Opening of Mitochondrial Big Versus Small Ca2+-sensitive K+ Channels on Cardiac Cell and Mitochondrial Protection.

Authors:  David F Stowe; Meiying Yang; James S Heisner; Amadou K S Camara
Journal:  J Cardiovasc Pharmacol       Date:  2017-11       Impact factor: 3.105

2.  Electrical conduction along endothelial cell tubes from mouse feed arteries: confounding actions of glycyrrhetinic acid derivatives.

Authors:  Erik J Behringer; Matthew J Socha; Luis Polo-Parada; Steven S Segal
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

3.  Activation of endothelial and epithelial K(Ca) 2.3 calcium-activated potassium channels by NS309 relaxes human small pulmonary arteries and bronchioles.

Authors:  Christel Kroigaard; Thomas Dalsgaard; Gorm Nielsen; Britt E Laursen; Hans Pilegaard; Ralf Köhler; Ulf Simonsen
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

4.  Chlorzoxazone, an SK-type potassium channel activator used in humans, reduces excessive alcohol intake in rats.

Authors:  F Woodward Hopf; Jeffrey A Simms; Shao-Ju Chang; Taban Seif; Selena E Bartlett; Antonello Bonci
Journal:  Biol Psychiatry       Date:  2010-12-31       Impact factor: 13.382

5.  KCa 3.1 channels maintain endothelium-dependent vasodilatation in isolated perfused kidneys of spontaneously hypertensive rats after chronic inhibition of NOS.

Authors:  Serge Simonet; Marc Isabelle; Mélanie Bousquenaud; Nicolas Clavreul; Michel Félétou; Christine Vayssettes-Courchay; Tony J Verbeuren
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

Review 6.  Pharmacological gating modulation of small- and intermediate-conductance Ca(2+)-activated K(+) channels (KCa2.x and KCa3.1).

Authors:  Palle Christophersen; Heike Wulff
Journal:  Channels (Austin)       Date:  2015-07-28       Impact factor: 2.581

7.  Membrane potential governs calcium influx into microvascular endothelium: integral role for muscarinic receptor activation.

Authors:  Erik J Behringer; Steven S Segal
Journal:  J Physiol       Date:  2015-09-13       Impact factor: 5.182

8.  Impact of Aging on Calcium Signaling and Membrane Potential in Endothelium of Resistance Arteries: A Role for Mitochondria.

Authors:  Erik J Behringer; Steven S Segal
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2017-11-09       Impact factor: 6.053

9.  Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure.

Authors:  Ananthakrishnan Sankaranarayanan; Girija Raman; Christoph Busch; Tim Schultz; Pavel I Zimin; Joachim Hoyer; Ralf Köhler; Heike Wulff
Journal:  Mol Pharmacol       Date:  2008-10-27       Impact factor: 4.436

10.  NS309 restores EDHF-type relaxation in mesenteric small arteries from type 2 diabetic ZDF rats.

Authors:  E Brøndum; H Kold-Petersen; U Simonsen; Christian Aalkjaer
Journal:  Br J Pharmacol       Date:  2009-12-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.